陕西省短缺药品储备基地启动运营

2018-09-30 蔺娟 新华网

记者27日从陕西省卫生计生委获悉,陕西省11家短缺药品储备基地日前正式启动运营。储备基地将承担陕西全省短缺药品、急抢救药品和罕见病用药的储备工作,确保药品市场供应。

记者27日从陕西省卫生计生委获悉,陕西省11家短缺药品储备基地日前正式启动运营。储备基地将承担陕西全省短缺药品、急抢救药品和罕见病用药的储备工作,确保药品市场供应。

据介绍,陕西省卫生计生委日前与国药控股陕西有限公司、陕西天士力医药有限公司等11家企业签订了《陕西省短缺药品储备基地协议书》。这11家短缺药品储备基地将根据陕西省短缺药品清单,结合市场动态,合理确定储备品种和储备数量,保障短缺药品特别是急抢救药品的高效调剂、及时到位,并定期在陕西省卫生计生委和陕西省药械集中采购平台更新储备信息。

同时,陕西省卫生计生委要求做好临床需求侧与生产流通供给侧对接,及时发现医疗卫生机构用药短缺苗头,协商调剂短缺药品,减少因供需双方信息沟通不畅导致的药品短缺。短缺药品储备基地还承担国家短缺药品监测哨点职责,实行短缺药品监测信息每月零报告制度,并具有24小时应急配送能力。

此外,陕西还将加强对短缺药品生产和配送企业的监测预警,强化药品及原料药市场监管,依法查处哄抬价格和垄断等各类违法违规行为,并建立失信经营者黑名单制度,对屡查屡犯的短缺药品及原料药垄断案件相关经营者,依法制定禁止其从事医药行业的措施,严格执行药品采购诚信记录和市场清退机制。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1536330, encodeId=473915363301c, content=<a href='/topic/show?id=ae8fe324387' target=_blank style='color:#2F92EE;'>#短缺药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73243, encryptionId=ae8fe324387, topicName=短缺药品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c7712689228, createdName=chaojitidian, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618025, encodeId=e61e16180252d, content=<a href='/topic/show?id=c103e3239e8' target=_blank style='color:#2F92EE;'>#短缺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73239, encryptionId=c103e3239e8, topicName=短缺药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d1719824693, createdName=passed water, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628126, encodeId=0718162812693, content=<a href='/topic/show?id=b19de323897' target=_blank style='color:#2F92EE;'>#短缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73238, encryptionId=b19de323897, topicName=短缺)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347348, encodeId=09b934e3489e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Sep 30 09:06:27 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347341, encodeId=201934e34150, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Sep 30 09:01:48 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347303, encodeId=650134e30358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 30 06:00:24 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1536330, encodeId=473915363301c, content=<a href='/topic/show?id=ae8fe324387' target=_blank style='color:#2F92EE;'>#短缺药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73243, encryptionId=ae8fe324387, topicName=短缺药品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c7712689228, createdName=chaojitidian, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618025, encodeId=e61e16180252d, content=<a href='/topic/show?id=c103e3239e8' target=_blank style='color:#2F92EE;'>#短缺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73239, encryptionId=c103e3239e8, topicName=短缺药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d1719824693, createdName=passed water, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628126, encodeId=0718162812693, content=<a href='/topic/show?id=b19de323897' target=_blank style='color:#2F92EE;'>#短缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73238, encryptionId=b19de323897, topicName=短缺)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347348, encodeId=09b934e3489e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Sep 30 09:06:27 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347341, encodeId=201934e34150, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Sep 30 09:01:48 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347303, encodeId=650134e30358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 30 06:00:24 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1536330, encodeId=473915363301c, content=<a href='/topic/show?id=ae8fe324387' target=_blank style='color:#2F92EE;'>#短缺药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73243, encryptionId=ae8fe324387, topicName=短缺药品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c7712689228, createdName=chaojitidian, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618025, encodeId=e61e16180252d, content=<a href='/topic/show?id=c103e3239e8' target=_blank style='color:#2F92EE;'>#短缺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73239, encryptionId=c103e3239e8, topicName=短缺药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d1719824693, createdName=passed water, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628126, encodeId=0718162812693, content=<a href='/topic/show?id=b19de323897' target=_blank style='color:#2F92EE;'>#短缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73238, encryptionId=b19de323897, topicName=短缺)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347348, encodeId=09b934e3489e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Sep 30 09:06:27 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347341, encodeId=201934e34150, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Sep 30 09:01:48 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347303, encodeId=650134e30358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 30 06:00:24 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1536330, encodeId=473915363301c, content=<a href='/topic/show?id=ae8fe324387' target=_blank style='color:#2F92EE;'>#短缺药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73243, encryptionId=ae8fe324387, topicName=短缺药品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c7712689228, createdName=chaojitidian, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618025, encodeId=e61e16180252d, content=<a href='/topic/show?id=c103e3239e8' target=_blank style='color:#2F92EE;'>#短缺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73239, encryptionId=c103e3239e8, topicName=短缺药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d1719824693, createdName=passed water, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628126, encodeId=0718162812693, content=<a href='/topic/show?id=b19de323897' target=_blank style='color:#2F92EE;'>#短缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73238, encryptionId=b19de323897, topicName=短缺)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347348, encodeId=09b934e3489e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Sep 30 09:06:27 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347341, encodeId=201934e34150, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Sep 30 09:01:48 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347303, encodeId=650134e30358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 30 06:00:24 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-09-30 明月清辉

    谢谢分享,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1536330, encodeId=473915363301c, content=<a href='/topic/show?id=ae8fe324387' target=_blank style='color:#2F92EE;'>#短缺药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73243, encryptionId=ae8fe324387, topicName=短缺药品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c7712689228, createdName=chaojitidian, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618025, encodeId=e61e16180252d, content=<a href='/topic/show?id=c103e3239e8' target=_blank style='color:#2F92EE;'>#短缺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73239, encryptionId=c103e3239e8, topicName=短缺药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d1719824693, createdName=passed water, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628126, encodeId=0718162812693, content=<a href='/topic/show?id=b19de323897' target=_blank style='color:#2F92EE;'>#短缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73238, encryptionId=b19de323897, topicName=短缺)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347348, encodeId=09b934e3489e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Sep 30 09:06:27 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347341, encodeId=201934e34150, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Sep 30 09:01:48 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347303, encodeId=650134e30358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 30 06:00:24 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-09-30 liumin1987

    嗯嗯,学习了。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1536330, encodeId=473915363301c, content=<a href='/topic/show?id=ae8fe324387' target=_blank style='color:#2F92EE;'>#短缺药品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73243, encryptionId=ae8fe324387, topicName=短缺药品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c7712689228, createdName=chaojitidian, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618025, encodeId=e61e16180252d, content=<a href='/topic/show?id=c103e3239e8' target=_blank style='color:#2F92EE;'>#短缺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73239, encryptionId=c103e3239e8, topicName=短缺药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d1719824693, createdName=passed water, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628126, encodeId=0718162812693, content=<a href='/topic/show?id=b19de323897' target=_blank style='color:#2F92EE;'>#短缺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73238, encryptionId=b19de323897, topicName=短缺)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 01 15:07:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347348, encodeId=09b934e3489e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Sun Sep 30 09:06:27 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347341, encodeId=201934e34150, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Sep 30 09:01:48 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347303, encodeId=650134e30358, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 30 06:00:24 CST 2018, time=2018-09-30, status=1, ipAttribution=)]

相关资讯

保健用品企业分类监管 陕西“打个样”

从2018年9月9日起,陕西省将对保健用品生产企业实施信用等级评定及分类监管。

陕西免费医学生按二本分数线录取

近日,陕西省教育厅、人社厅、卫生部门发布通知,提出国家免费医学生执行本科二批分数线,并在录取后与培养高校和定向就业所在地签订到有关基层医疗卫生机构服务6年的协议。

考生注意!定向医学生出新政

陕西省招办规定:国家免费医学生只招收农村学生 ,须在基层服务6年。

率先开始!陕西144人参加了确有专长医师资格考核试考,很大72岁

中医药法实施近一周年,陕西省在全国率先组织中医医术确有专长人员医师资格先行考核。6月13~14日,西安市未央区、铜川市144名符合条件的报名者参加了先行考核。

闫树江在陕西调研中医药法实施情况

国家中医药管理局副局长闫树江前往陕西调研中医药法实施情况并与相关人员座谈。座谈会上, 西北及东北地区8省(区)中医药管理部门负责人汇报了本省中医药法执行情况,陕西省人大、法制办、卫生计生委、食药监局以及西安、铜川等地中医药管理部门、中医医疗机构、备案中医诊所、中医确有专长人员等围绕中医药法实施,提出意见及建议。

陕西培养全科医生下基层

近日,陕西省政府办公厅印发《陕西省改革完善全科医生培养与使用激励机制实施方案》,引导和鼓励更多优秀全科医生在基层服务。根据《方案》,到2030年,该省将基本实现城乡每万名居民拥有5名合格全科医生的目标,基本满足三秦百姓获得更好医疗健康服务的需求。